scholarly journals Glatiramer Acetate (Copolymer-1, Copaxone) Promotes Th2 Cell Development and Increased IL-10 Production Through Modulation of Dendritic Cells

2003 ◽  
Vol 170 (9) ◽  
pp. 4483-4488 ◽  
Author(s):  
Pedro L. Vieira ◽  
Heleen C. Heystek ◽  
Jan Wormmeester ◽  
Eddy A. Wierenga ◽  
Martien L. Kapsenberg
2005 ◽  
Vol 174 (2) ◽  
pp. 742-751 ◽  
Author(s):  
Jie Sun ◽  
Matthew Walsh ◽  
Alejandro V. Villarino ◽  
Laura Cervi ◽  
Christopher A. Hunter ◽  
...  

2000 ◽  
Vol 289 (3) ◽  
pp. 205-208 ◽  
Author(s):  
Dominik Dabbert ◽  
Sabine Rösner ◽  
Marcus Krämer ◽  
Ulrike Schöll ◽  
Hayrettin Tumani ◽  
...  

2001 ◽  
Vol 8 (6) ◽  
pp. 1196-1203 ◽  
Author(s):  
Roumen Balabanov ◽  
Deena Lisak ◽  
Thomas Beaumont ◽  
Robert P. Lisak ◽  
Paula Dore-Duffy

ABSTRACT Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system in which peripheral blood monocytes play an important role. We have previously reported that patients with chronic progressive MS (CPMS) have significantly increased numbers of circulating monocytes which express the urokinase plasminogen activator receptor (uPAR). In the present study, we examined the expression of uPAR on monocytes in patients with relapsing-remitting multiple sclerosis (RRMS) not currently participating in a clinical trial and in patients with RRMS who were enrolled in a double-blind multicenter clinical trial designed to examine the effect of glatiramer acetate (copolymer 1; Copaxone) on relapsing disease. Patients with CPMS have sustained high levels of circulating uPAR-positive (uPAR+) monocytes. In comparison, patients with RRMS displayed variable levels of circulating uPAR+ monocytes. Mean values for uPAR in patients with RRMS were above those seen for controls but were not as high as those observed for patients with secondary progressive MS. Patients with RRMS in the clinical trial also had variable levels of monocyte uPAR. However, patients in the treatment group displayed lower levels following 2 years of treatment. In both placebo-treated and glatiramer acetate-treated patients, the percentage of circulating uPAR+ monocytes, as well as the density of uPAR expressed per cell (mean linear fluorescence intensity), increased just prior to the onset of a clinically documented exacerbation. Values fell dramatically with the development of clinical symptoms. uPAR levels in all groups correlated with both clinical activity and severity. Results indicate that monocyte activation is impatient in MS and that glatiramer acetate may have a significant effect on monocyte activation in patients with RRMS.


Blood ◽  
2007 ◽  
Vol 110 (2) ◽  
pp. 553-560 ◽  
Author(s):  
Naoki Tokumasa ◽  
Akira Suto ◽  
Shin-ichiro Kagami ◽  
Shunsuke Furuta ◽  
Koichi Hirose ◽  
...  

Abstract It is well documented that dendritic cells (DCs), representative antigen-presenting cells, are important sources of Th1-promoting cytokines and are actively involved in the regulation of T-helper–cell differentiation. However, the intracellular event that regulates this process is still largely unknown. In this study, we examined the role of Tyk2, a JAK kinase that is involved in the signaling pathway under IL-12 and IL-23, in DC functions. While the differentiation and maturation of DCs was normal in Tyk2-deficient (Tyk2−/−) mice, IL-12–induced Stat4 phosphorylation was diminished in Tyk2−/− DCs. IL-12–induced IFN-γ production was also significantly diminished in Tyk2−/− DCs to levels similar to those in Stat4−/− DCs. Interestingly, Tyk2−/− DCs were defective in IL-12 and IL-23 production upon stimulation with CpG ODN. Furthermore, Tyk2−/− DCs were impaired in their ability to induce Th1-cell differentiation but not Th2-cell differentiation. Taken together, these results indicate that the expression of Tyk2 in DCs is crucial for the production of Th1-promoting cytokines such as IL-12 and IFN-γ from DCs and thereby for the induction of antigen-specific Th1-cell differentiation.


Sign in / Sign up

Export Citation Format

Share Document